Clorox stock hits 52-week low at 120.68 USD

Clorox Co (NYSE:CLX)’s stock recently reached a 52-week low, hitting a price of 120.68 USD. This milestone comes amid a challenging year for the company, which has seen its stock value decrease by 11.62% over the past 12 months. Despite the decline, Clorox maintains a solid 4% dividend yield and has raised its dividend for 48 consecutive years. According to InvestingPro analysis, the company’s RSI indicates oversold conditions, suggesting potential value for investors. The decline in Clorox’s stock price reflects broader market trends and company-specific challenges that have impacted investor sentiment. The 52-week low highlights the ongoing volatility in the market and underscores the need for strategic adjustments as Clorox navigates through these turbulent times. With a gross profit margin of 45% and positive earnings forecasts, the company shows fundamental strength despite current market pressures. InvestingPro analysis suggests the stock is currently undervalued, with 10+ additional exclusive insights available to subscribers.

In other recent news, Clorox reported its fiscal third-quarter earnings, which fell short of expectations with an earnings per share (EPS) of $1.45, missing estimates from Raymond (NSE:RYMD) James and consensus figures. Organic sales declined by 2% year-over-year, contrary to the expected flat growth. Despite these challenges, Clorox saw an increase in its gross margin by 240 basis points to 44.6%, exceeding various analysts’ expectations. The company adjusted its organic sales growth forecast for the fiscal year 2025 to 4-5%, incorporating a sales pullforward expected to contribute 2-3 percentage points.

Jefferies analyst Kaumil Gajrawala adjusted Clorox’s price target to $167 from $177, maintaining a Buy rating, citing a challenging environment for the Home and Personal Care sector. Wells Fargo (NYSE:WFC) also revised its price target for Clorox to $142 from $145, keeping an Equal Weight rating, while noting the company’s valuation has declined. JPMorgan reduced Clorox’s price target to $144 from $151, maintaining a Neutral rating, due to a miss in organic sales growth and adjusted EPS expectations.

In boardroom developments, Clorox announced the appointment of Gina Boswell, CEO of Bath & Body Works, to its board of directors, effective May 19, 2025. Boswell’s addition will expand the board to 12 members, bringing her extensive experience from consumer goods companies like Unilever (LON:ULVR) and Estée Lauder. These recent developments provide investors with insights into Clorox’s current financial performance and strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.